This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment satisfaction as measured by the treatment satisfaction questionnaire for medication (TSQM) at week 24 among moderate to severe HS patients.
Male or Female adult patients ≥18 years of age at the time of data collection.
Patient with a confirmed diagnosis of active moderate to severe HS.
Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label.
Patients can be using antibiotics or have undergone surgery as per routine clinical practice.
Patients not fulfilling any of the above-mentioned inclusion criteria.
Patient's refusal to be included in the study or refusal to sign the ICF.
A history of off-label indication uses of biological treatment or JAK inhibitor.